News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
781,346 Results
Type
Article (76695)
Company Profile (733)
Press Release (703918)
Section
Business (214569)
Career Advice (3663)
Deals (37948)
Drug Delivery (115)
Drug Development (87943)
Employer Resources (180)
FDA (17430)
Job Trends (16715)
News (370142)
Policy (36799)
Tag
Academia (2968)
Alliances (52792)
Alzheimer's disease (1335)
Approvals (17338)
Artificial intelligence (153)
Bankruptcy (359)
Best Places to Work (12513)
Biotechnology (504)
Breast cancer (131)
Cancer (1174)
Cardiovascular disease (107)
Career advice (3107)
Cell therapy (268)
Clinical research (69388)
Collaboration (417)
Compensation (202)
COVID-19 (2780)
C-suite (106)
Data (1151)
Diabetes (167)
Diagnostics (6650)
Earnings (83040)
Employer resources (157)
Events (123028)
Executive appointments (328)
FDA (17993)
Funding (374)
Gene therapy (201)
GLP-1 (687)
Government (4973)
Healthcare (20675)
Infectious disease (2873)
Inflammatory bowel disease (121)
Interviews (704)
IPO (17472)
Job creations (4631)
Job search strategy (2559)
Layoffs (486)
Legal (8831)
Lung cancer (190)
Manufacturing (201)
Medical device (14345)
Medtech (14350)
Mergers & acquisitions (20556)
Metabolic disorders (466)
Neuroscience (1636)
NextGen Class of 2024 (7571)
Non-profit (5054)
Northern California (1516)
Obesity (267)
Opinion (243)
Patents (111)
People (62641)
Pharmaceutical (146)
Phase I (21472)
Phase II (30222)
Phase III (22736)
Pipeline (466)
Postmarket research (3225)
Preclinical (9596)
Radiopharmaceuticals (258)
Rare diseases (243)
Real estate (6979)
Regulatory (24418)
Research institute (2631)
Resumes & cover letters (581)
Southern California (1343)
Startups (3970)
United States (14538)
Vaccines (636)
Weight loss (216)
Date
Today (139)
Last 7 days (827)
Last 30 days (4005)
Last 365 days (38300)
2024 (35143)
2023 (42500)
2022 (53838)
2021 (58675)
2020 (57630)
2019 (51246)
2018 (38965)
2017 (36125)
2016 (36480)
2015 (42390)
2014 (36799)
2013 (34152)
2012 (34716)
2011 (34892)
2010 (34197)
Location
Africa (1129)
Arizona (193)
Asia (45826)
Australia (8192)
California (3524)
Canada (1297)
China (262)
Colorado (156)
Connecticut (172)
Europe (106353)
Florida (473)
Georgia (127)
Illinois (406)
Indiana (215)
Kansas (102)
Maryland (628)
Massachusetts (2854)
Michigan (177)
Minnesota (297)
New Jersey (1004)
New York (999)
North Carolina (841)
Northern California (1516)
Ohio (149)
Pennsylvania (869)
South America (1492)
Southern California (1343)
Texas (504)
Washington State (401)
781,346 Results for "the new england journal of medicine".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine
Oncocyte Corporation, a precision diagnostics company, announced that favorable data regarding its lead product VitaGraft™ Kidney was published in the New England Journal of Medicine.
May 30, 2024
·
8 min read
Drug Development
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the New England Journal of Medicine(NEJM) has published results from a positive Phase 3 trial for Dupixent® (dupilumab) in children aged 1 to 11 years with eosinophilic esophagitis (EoE).
June 26, 2024
·
22 min read
Press Releases
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
November 18, 2024
·
8 min read
Press Releases
Balt Announces Publication in New England Journal of Medicine of The Squid Trial for the Embolization of the Middle Meningeal Artery (STEM) for the Treatment of chronic Sub-Dural Hematoma
November 21, 2024
·
3 min read
Drug Development
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the primary study results from its CAHtalyst™ Pediatric Phase 3 study investigating crinecerfont for the treatment of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency have been published in The New England Journal of Medicine online edition and will appear in a future print issue of the journal.
June 3, 2024
·
11 min read
Drug Development
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the primary study results from its CAHtalyst™ Phase 3 study investigating crinecerfont for the treatment of adults ages 18 and older with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency have been published in The New England Journal of Medicine online edition and will appear in a future print issue of the journal.
June 3, 2024
·
11 min read
BioMidwest
The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced online publication of the BLUE-C study results in The New England Journal of Medicine.
March 13, 2024
·
8 min read
Press Releases
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
November 15, 2024
·
17 min read
Press Releases
Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference
November 18, 2024
·
11 min read
BioMidwest
The New England Journal of Medicine Publishes Complete Data from ENRICH, the First Positive Trial to Improve Functional and Economic Outcomes for Intracerebral Hemorrhage (ICH)
NICO Corporation, a pioneer and leader in minimally invasive parafascicular surgery (MIPS), today announced the entire results of the ENRICH (Early MiNimally-invasive Removal of ICH) trial have been published in the New England Journal of Medicine.
April 11, 2024
·
8 min read
1 of 78,135
Next
